Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 0.46 |
| ▸ | TK1 | P04183 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | TK2 | O00142 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4809531 | 0.85 | TK1 (0.44) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL8110184 | 0.85 | LMNA (0.51) | TK1SMN1; SMN2LMNACYP1A2CYP3A4 | |
| SCHEMBL5052901 | 0.85 | PYGM (0.46) | PYGMTK1SMN1; SMN2LMNACYP1A2 | |
| SCHEMBL28040328 | 0.83 | PYGM (0.45) | PYGMTK1SMN1; SMN2LMNACYP1A2 | |
| SCHEMBL28749266 | 0.82 | PYGM (0.44) | PYGMTK1SMN1; SMN2LMNACYP1A2 | |
| SCHEMBL28786348 | 0.78 | SLC28A1 (0.45) | — | |
| SCHEMBL5614068 | 0.74 | PYGM (0.50) | PYGMTK1SMN1; SMN2LMNAALOX12 | |
| SCHEMBL4542149 | 0.72 | TK1 (0.43) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL6830454 | 0.72 | TK1 (0.43) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL29364921 | 0.72 | TK1 (0.45) | TK1LMNATSHRBLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113528446-A | Culture medium and pharmaceutical composition for chemically inducing direct reprogramming transformation of human tumor cells into non-tumorigenic cells | 海门雨霖细胞科技有限责任公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-106806894-B | Method for inducing direct reprogramming of human tumor cells into non-tumorigenic cells by using small molecule composition | 海门雨霖细胞科技有限责任公司 | 2021-06-25 | — | — | CN | disclosed |
| EP-3384929-B1 | METHOD FOR USING SMALL MOLECULE COMPOUNDS TO INDUCE HUMAN TUMOR CELLS TO BE DIRECTLY REPROGRAMMED INTO NON-ONCOGENIC CELLS | TRANSCEND CYTOTHERAPY CO LTD (CN) | 2021-06-16 | — | — | EP | disclosed |
| US-10463641-B2 | Method for using small molecule compounds to induce human tumor cells to be directly reprogrammed into non-oncogenic cells | TRANSCEND CYTOTHERAPY CO., LTD (CN) | 2019-11-05 | — | — | US | disclosed |
| US-20180353454-A1 | Method for Using Small Molecule Compounds to Induce Human Tumor Cells to Be Directly Reprogrammed Into Non-Oncogenic Cells | Transcend Cytotherapy Co.,Ltd (CN) | 2018-12-13 | — | — | US | disclosed |
| EP-3384929-A1 | METHOD FOR USING SMALL MOLECULE COMPOUNDS TO INDUCE HUMAN TUMOR CELLS TO BE DIRECTLY REPROGRAMMED INTO NON-ONCOGENIC CELLS | Transcend Cytotherapy Co., Ltd (CN) | 2018-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463641-B2 | Method for using small molecule compounds to induce human tumor cells to be directly reprogrammed into non-oncogenic cells | MCL1, HRAS, TP53 | PYGM 3083/4885TK1 1123/4885SMN1; SMN2 4486/4885 |
| US-20180353454-A1 | Method for Using Small Molecule Compounds to Induce Human Tumor Cells to Be Directly Reprogrammed Into Non-Oncogenic Cells | MCL1, HRAS, TP53 | PYGM 3083/4885TK1 1123/4885SMN1; SMN2 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.